Venezuela (Bolivarian Republic of)

Population 2018: 29 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>14 (11–17)</td>
<td>48 (37–60)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>1.2 (0.41–2.5)</td>
<td>4.2 (1.4–8.6)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence**</td>
<td>0.4 (0.15–0.77)</td>
<td>1.4 (0.52–2.7)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>0.73 (0.69–0.78)</td>
<td>2.5 (2.4–2.7)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.27 (0.088–0.55)</td>
<td>0.94 (0.3–1.9)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

- % tested with rapid diagnostics at time of diagnosis
- % with known HIV status
- % pulmonary
- % bacteriologically confirmed**
- % children aged 0-14 years
- % women
- % men

Total cases notified: 11 394

Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2018: 80% (63–100)
- TB patients facing catastrophic total costs: 7% (5–10)
- TB case fatality ratio (estimated mortality/estimated incidence), 2018: 7% (5–10)

TB/HIV care in new and relapse TB patients, 2018

- Patients with known HIV status who are HIV-positive: 473, 7%
  - on antiretroviral therapy: 300, 63%

Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance**
  - New cases: 6%
  - Previously treated cases: 44%

Laboratory-confirmed cases* MDR/RR-TB: 43, XDR-TB: 0

Patients started on treatment** MDR/RR-TB: 41, XDR-TB: 0

MDR/RR-TB cases tested for resistance to second-line drugs: 37

Treatment success rate and cohort size

- New and relapse cases registered in 2017: 82% (10 647)
- Previously treated cases, excluding relapse, registered in 2017: 74% (305)
- HIV-positive TB cases registered in 2017: 88% (528)
- MDR/RR-TB cases started on second-line treatment in 2016: 72% (57)
- XDR-TB cases started on second-line treatment in 2016: 0

TB preventive treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 2%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 96% (71–100)

TB financing, 2019

- National TB budget (US$ millions): 2.7
- Funding source: 21% domestic, 0% international, 79% unfunded

*Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2019-10-19

Data: www.who.int/tb/data